Inebilizumab Biosimilar - Anti-CD19 mAb - Research Grade
Source
CAS 1299440-37-1
Species
Humanized
Expression system
Mammalian cells
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Inebilizumab,MEDI-551,CD19,anti-CD19
Reference
PX-TA1385
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG1-kappa
Clonality
Monoclonal Antibody
Description of Inebilizumab Biosimilar - Anti-CD19 mAb - Research Grade
General information on Anti-CD19[Homo sapiens] (Inebilizumab) Monoclonal Antibody
Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody that targets the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, which may be usefull to treat neuromyelitis optica spectrum disorder (NMOSD)through B-cell depletion.
Reviews
There are no reviews yet.